Legal & General Group Plc Has $1.06 Billion Holdings in Pfizer, Inc. (PFE)
Legal & General Group Plc lifted its position in shares of Pfizer, Inc. (NYSE:PFE) by 0.9% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 31,463,283 shares of the biopharmaceutical company’s stock after purchasing an additional 292,839 shares during the period. Pfizer comprises about 0.9% of Legal & General Group Plc’s holdings, making the stock its 18th largest position. Legal & General Group Plc owned 1.88% of Pfizer worth $1,056,857,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Shine Investment Advisory Services Inc. acquired a new stake in shares of Pfizer during the second quarter worth about $102,000. D. Scott Neal Inc. increased its position in shares of Pfizer by 19.3% during the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 504 shares in the last quarter. Franklin Parlapiano Turner & Welch LLC acquired a new stake in shares of Pfizer during the first quarter worth about $121,000. Cascade Investment Advisors Inc. increased its position in shares of Pfizer by 89.1% during the second quarter. Cascade Investment Advisors Inc. now owns 4,669 shares of the biopharmaceutical company’s stock worth $157,000 after purchasing an additional 2,200 shares in the last quarter. Finally, Perennial Advisors LLC increased its position in shares of Pfizer by 7.9% during the second quarter. Perennial Advisors LLC now owns 5,132 shares of the biopharmaceutical company’s stock worth $172,000 after purchasing an additional 376 shares in the last quarter. Institutional investors and hedge funds own 69.34% of the company’s stock.
Shares of Pfizer, Inc. (NYSE PFE) opened at $35.37 on Monday. The company has a market capitalization of $210,830.00, a P/E ratio of 14.15, a PEG ratio of 2.50 and a beta of 1.01. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.15 and a current ratio of 1.43. Pfizer, Inc. has a 52 week low of $30.51 and a 52 week high of $36.78.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.02. The business had revenue of $13.17 billion for the quarter, compared to analyst estimates of $13.17 billion. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The company’s quarterly revenue was up .9% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.61 EPS. research analysts expect that Pfizer, Inc. will post 2.6 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Stockholders of record on Friday, November 10th will be paid a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 3.62%. The ex-dividend date is Thursday, November 9th. Pfizer’s dividend payout ratio (DPR) is 78.53%.
COPYRIGHT VIOLATION WARNING: This article was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this article on another publication, it was copied illegally and republished in violation of United States and international copyright legislation. The original version of this article can be read at https://www.dailypolitical.com/2017/11/20/legal-general-group-plc-has-1-06-billion-holdings-in-pfizer-inc-pfe.html.
In other news, insider Alexander R. Mackenzie sold 7,350 shares of the business’s stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $34.00, for a total transaction of $249,900.00. Following the sale, the insider now owns 132,124 shares of the company’s stock, valued at approximately $4,492,216. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Ian C. Read sold 197,168 shares of the business’s stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $34.00, for a total value of $6,703,712.00. Following the sale, the chief executive officer now directly owns 580,318 shares in the company, valued at approximately $19,730,812. The disclosure for this sale can be found here. Insiders have sold a total of 366,557 shares of company stock worth $12,532,406 in the last three months. Corporate insiders own 0.06% of the company’s stock.
A number of analysts have recently commented on PFE shares. Cowen and Company set a $43.00 target price on Pfizer and gave the stock a “buy” rating in a research report on Monday, August 14th. Jefferies Group LLC set a $35.00 target price on Pfizer and gave the stock a “neutral” rating in a research report on Thursday, August 24th. Berenberg Bank reiterated a “hold” rating and set a $36.00 target price (down previously from $39.00) on shares of Pfizer in a research report on Tuesday, August 15th. Deutsche Bank AG set a $38.00 target price on Pfizer and gave the stock a “buy” rating in a research report on Wednesday, October 11th. Finally, Goldman Sachs Group, Inc. (The) set a $36.00 target price on Pfizer and gave the stock a “neutral” rating in a research report on Wednesday, November 1st. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $38.48.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.